BillionToOne Hits Profitability, Raises Guidance on 84% Revenue Surge

MENLO PARK, CA – May 06, 2026 – BillionToOne, Inc. (NASDAQ: BLLN) today announced a landmark first quarter for 2026, reporting an 84% surge in revenue and a decisive pivot to profitability that significantly outpaced market expectations. The molecular diagnostics company posted total revenues of $108.4 million, a substantial increase from $59.0 million in the same period last year, and converted a prior-year operating loss into a robust $17.8 million in operating income.

This strong financial performance prompted the company to raise its full-year revenue guidance to a range of $450 million to $465 million, signaling deep confidence in its growth trajectory. The results were driven by soaring demand for its prenatal and oncology tests and were accompanied by the launch of a potentially transformative non-invasive prenatal confirmation assay, Unity Confirm™.

A Financial Turning Point

BillionToOne's first-quarter results mark a significant turning point, demonstrating a successful transition from a growth-focused, loss-making enterprise to a profitable industry player. The company reported a net income of $18.0 million, or $0.34 per diluted share, a dramatic reversal from the net loss of $4.0 million, or $(0.39) per share, in the first quarter of 2025.

The impressive top-line growth was powered by a 44% increase in the number of tests delivered, totaling 188,000 for the quarter. This volume growth was amplified by a 28% increase in the overall average selling price (ASP) per test, which rose to $571. This combination led to a significant expansion in gross profit margin, which climbed to 73% from 64% a year prior. The company generated $11.0 million in cash flow from operations after accounting for capital expenditures, underscoring its newfound operational efficiency.

"Our first quarter performance underscores the continued momentum we are building through our differentiated technology platform, category-defining products, and disciplined execution," said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne, in a statement. "We remain focused on addressing some of healthcare’s most complex challenges. As we move through 2026, we believe we are only beginning to realize the full potential of our platform.”

Redefining Prenatal Safety with Unity Confirm™

Beyond the stellar financials, BillionToOne unveiled a significant technological advancement with the launch of Unity Confirm™. This new assay is designed to provide a non-invasive method for confirming high-risk results from initial prenatal screenings, offering a safer alternative to conventional invasive procedures like amniocentesis or chorionic villus sampling (CVS), which carry a small but inherent risk of pregnancy loss.

The global market for non-invasive prenatal testing (NIPT) has grown rapidly as a preferred screening method, but a critical gap has remained: what to do after a high-risk screening result. Unity Confirm™ aims to fill this void by leveraging BillionToOne's proprietary Fetal Cell Capture™ technology. Unlike standard NIPTs that analyze fragments of cell-free DNA (cfDNA) from the placenta, Unity Confirm™ isolates and analyzes whole, intact fetal cells from a simple maternal blood draw. This direct analysis of the fetus's own genetic material has the potential to provide a more definitive diagnostic answer, reducing patient anxiety and the number of invasive procedures performed annually.

This innovation could reshape the clinical pathway for millions of expectant parents, aligning with a broader market trend toward safer, more accurate, and less invasive diagnostic solutions in reproductive health.

Dual Engines of Growth in Diagnostics

BillionToOne's success is not confined to a single product line. The company's Q1 results reveal a robust, diversified strategy with two powerful engines driving growth: prenatal and oncology diagnostics.

Prenatal testing remains the company's commercial bedrock, generating $96.5 million in revenue, a 72% increase year-over-year. This established segment continues to show remarkable strength and market penetration. Simultaneously, the company's oncology division is emerging as a formidable growth catalyst. Oncology clinical testing revenue quadrupled, rocketing to $10.7 million from just $2.2 million in the prior-year quarter, showcasing the increasing adoption of its liquid biopsy products for cancer monitoring and therapy selection.

This dual-pronged approach is supported by strong commercial execution. The company announced it has significantly expanded its payor contracts, now covering 300 million lives in the United States. This achievement is critical in the diagnostics industry, as it ensures broad patient access, simplifies reimbursement, and creates a predictable revenue stream. Securing such extensive coverage demonstrates to payors and clinicians the proven clinical utility of BillionToOne's tests.

Fueled by its patented Quantitative Counting Templates™ (QCT™) molecular counting platform, which underpins its entire product portfolio, the company is successfully tackling complex challenges in both reproductive health and precision oncology. With a strong balance sheet, a clear path to sustained profitability, and a pipeline of innovative products, BillionToOne has firmly established itself as a key player in the future of molecular diagnostics.